loading
Schlusskurs vom Vortag:
$190.35
Offen:
$197.58
24-Stunden-Volumen:
1.55M
Relative Volume:
3.42
Marktkapitalisierung:
$11.71B
Einnahmen:
$393.98M
Nettoeinkommen (Verlust:
$-367.45M
KGV:
-30.43
EPS:
-6.293
Netto-Cashflow:
$-460.07M
1W Leistung:
+9.75%
1M Leistung:
+13.87%
6M Leistung:
+58.43%
1J Leistung:
+52.00%
1-Tages-Spanne:
Value
$175.19
$199.99
1-Wochen-Bereich:
Value
$173.33
$199.99
52-Wochen-Spanne:
Value
$111.09
$199.99

Ascendis Pharma A S Adr Stock (ASND) Company Profile

Name
Firmenname
Ascendis Pharma A S Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
1,017
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-13
Name
Neueste SEC-Einreichungen
Name
ASND's Discussions on Twitter

Vergleichen Sie ASND mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ASND
Ascendis Pharma A S Adr
191.49 11.05B 393.98M -367.45M -460.07M -6.293
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
366.54 98.88B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.00 58.84B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
438.93 56.12B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
661.83 41.20B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
288.18 35.49B 3.81B -644.79M -669.77M -6.24

Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-03 Fortgesetzt Morgan Stanley Overweight
2025-05-05 Hochstufung Morgan Stanley Equal-Weight → Overweight
2025-04-16 Eingeleitet RBC Capital Mkts Outperform
2025-01-07 Eingeleitet UBS Buy
2024-09-05 Hochstufung Oppenheimer Perform → Outperform
2024-06-25 Hochstufung TD Cowen Hold → Buy
2024-05-31 Eingeleitet Stifel Buy
2023-12-20 Eingeleitet Jefferies Buy
2023-06-14 Fortgesetzt Credit Suisse Neutral
2023-04-05 Herabstufung Oppenheimer Outperform → Perform
2023-04-04 Herabstufung Morgan Stanley Overweight → Equal-Weight
2023-04-03 Herabstufung Credit Suisse Outperform → Neutral
2022-10-20 Eingeleitet Goldman Buy
2022-08-30 Fortgesetzt Berenberg Buy
2022-03-28 Fortgesetzt Wedbush Outperform
2022-03-15 Hochstufung BofA Securities Neutral → Buy
2022-03-01 Eingeleitet Citigroup Buy
2022-02-14 Hochstufung Oppenheimer Perform → Outperform
2022-01-06 Eingeleitet Cowen Market Perform
2021-12-08 Eingeleitet Wells Fargo Overweight
2021-10-20 Herabstufung BofA Securities Buy → Neutral
2021-03-30 Herabstufung Oppenheimer Outperform → Perform
2021-03-11 Fortgesetzt Stifel Buy
2020-12-17 Eingeleitet Berenberg Buy
2020-09-14 Fortgesetzt JP Morgan Overweight
2020-03-20 Eingeleitet Oppenheimer Outperform
2019-10-11 Eingeleitet Morgan Stanley Overweight
2019-03-25 Eingeleitet Evercore ISI Outperform
2019-01-24 Eingeleitet Cantor Fitzgerald Overweight
2019-01-24 Hochstufung Leerink Partners Mkt Perform → Outperform
2018-06-26 Eingeleitet Stifel Buy
2018-04-02 Bestätigt Leerink Partners Mkt Perform
2017-05-11 Eingeleitet JP Morgan Overweight
2017-03-09 Herabstufung Leerink Partners Outperform → Mkt Perform
2017-02-09 Eingeleitet Credit Suisse Outperform
2016-09-26 Eingeleitet Wedbush Outperform
Alle ansehen

Ascendis Pharma A S Adr Aktie (ASND) Neueste Nachrichten

pulisher
Aug 08, 2025

Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily

Aug 08, 2025
pulisher
Aug 08, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 92 - inkl

Aug 08, 2025
pulisher
Jul 31, 2025

Ascendis Pharma ADR Shows Rising Price Performance With Jump To 81 RS Rating - inkl

Jul 31, 2025
pulisher
Jul 25, 2025

Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 81 RS Rating - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Stocks Showing Rising Market Leadership: Gpo Aeroportuario ADR Earns 83 RS Rating - inkl

Jul 25, 2025
pulisher
Jul 14, 2025

Ascendis Pharma reports positive results from hypothyroid trial - MSN

Jul 14, 2025
pulisher
Jul 02, 2025

Fund managers' favourite health stocks - Investors' Chronicle

Jul 02, 2025
pulisher
Jun 30, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Jun 30, 2025
pulisher
Jun 26, 2025

European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize

Jun 26, 2025
pulisher
Jun 10, 2025

Canaccord holds Ascendis Pharma stock at $84 target - Investing.com

Jun 10, 2025
pulisher
Jun 09, 2025

BofA raises Ascendis Pharma stock target to $216 - Investing.com

Jun 09, 2025
pulisher
Jun 04, 2025

Ascendis Pharma ADR Scores Relative Strength Rating Upgrade - MSN

Jun 04, 2025
pulisher
Jun 03, 2025

Chagee Holdings ADR Scores Relative Strength Rating Upgrade - inkl

Jun 03, 2025
pulisher
Jun 02, 2025

BofA Securities raises Ascendis Pharma stock price target to $201 - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

European ADRs Climb With Biotech Stocks Leading The Charge - Finimize

Jun 02, 2025
pulisher
Jun 02, 2025

Ascendis Pharma stock rises following FDA priority review By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

Ascendis Pharma stock rises following FDA priority review - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

FDA prioritizes review of Ascendis Pharma’s growth disorder drug - Investing.com

Jun 02, 2025
pulisher
May 27, 2025

Stifel maintains Buy on Ascendis Pharma stock, target at $212 - Investing.com

May 27, 2025
pulisher
May 25, 2025

Ascendis Pharma’s SWOT analysis: strong product pipeline drives stock potential - Investing.com India

May 25, 2025
pulisher
May 15, 2025

Ascendis Pharma grants new employee warrants By Investing.com - Investing.com India

May 15, 2025
pulisher
May 14, 2025

Ascendis Pharma grants new employee warrants - Investing.com

May 14, 2025
pulisher
May 13, 2025

Ascendis Pharma reports growth in achondroplasia trial By Investing.com - Investing.com India

May 13, 2025
pulisher
May 13, 2025

Ascendis Pharma reports growth in achondroplasia trial - Investing.com

May 13, 2025
pulisher
May 12, 2025

Cantor maintains $200 target on Ascendis Pharma stock By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 09, 2025

European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize

May 09, 2025
pulisher
May 08, 2025

In the Green: Ascendis Pharma A/S ADR (ASND) Closes at 160.99, Up/Down -1.14 from Previous Day - DWinneX

May 08, 2025
pulisher
May 02, 2025

Ascendis Pharma stock target raised to $245 by JPMorgan - Investing.com

May 02, 2025
pulisher
May 02, 2025

Ascendis Pharma A/S ADR (ASND) stock on the rise: An overview - uspostnews.com

May 02, 2025
pulisher
May 01, 2025

Ascendis Pharma AS earnings missed by €0.11, revenue topped estimates - Investing.com

May 01, 2025
pulisher
Apr 30, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 30, 2025
pulisher
Apr 16, 2025

RBC Capital sets $205 target on Ascendis Pharma stock - Investing.com

Apr 16, 2025
pulisher
Apr 15, 2025

Banco Macro ADR Earns Relative Strength Rating Upgrade - inkl

Apr 15, 2025
pulisher
Apr 14, 2025

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 11, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Jump To 87 - Investor's Business Daily

Apr 11, 2025
pulisher
Apr 07, 2025

European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView

Apr 07, 2025
pulisher
Mar 27, 2025

UBS maintains Ascendis Pharma stock Buy rating, $196 target - Investing.com

Mar 27, 2025
pulisher
Mar 19, 2025

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView

Mar 19, 2025
pulisher
Mar 18, 2025

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Mar 18, 2025
pulisher
Mar 17, 2025

European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView

Mar 17, 2025
pulisher
Mar 13, 2025

European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView

Mar 13, 2025
pulisher
Mar 12, 2025

European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView

Mar 12, 2025
pulisher
Mar 09, 2025

Ascendis Pharma A/S Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 07, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView

Mar 07, 2025
pulisher
Mar 06, 2025

Ascendis Pharma at TD Cowen Conference: Strategic Growth in Rare Diseases - Investing.com

Mar 06, 2025
pulisher
Feb 26, 2025

Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com

Feb 26, 2025
pulisher
Feb 25, 2025

Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com

Feb 25, 2025
pulisher
Feb 20, 2025

Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga

Feb 20, 2025
pulisher
Feb 20, 2025

Stocks To Watch: Kontoor Brands Sees RS Rating Rise To 84 - Inkl

Feb 20, 2025
pulisher
Feb 19, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 82 - Investor's Business Daily

Feb 19, 2025

Finanzdaten der Ascendis Pharma A S Adr-Aktie (ASND)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$78.39
price up icon 0.24%
$37.58
price up icon 1.54%
$109.55
price up icon 0.23%
$28.66
price up icon 2.10%
$111.66
price up icon 0.28%
biotechnology ONC
$288.18
price down icon 3.39%
Kapitalisierung:     |  Volumen (24h):